XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Inventory
 3 Months Ended
Mar. 31, 2023
Inventory Disclosure [Abstract]  
Inventory Inventory
At March 31, 2023 and December 31, 2022, the Company’s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company’s partners.
The Company’s inventories consisted of the following (in thousands):
March 31, 2023December 31, 2022
Raw materials$8,869 $8,906 
Work-in-process15,613 14,990 
Finished goods4,397 4,814 
Total inventory$28,879 $28,710 
Reserves(1,413)(1,177)
Total inventory, net$27,466 $27,533